REG - GSK PLC - Positive Phase III results for Nucala in COPD

GSKAnnouncement

06/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240906:nRSF1545Da&default-theme=true

RNS Number : 1545D  GSK PLC  06 September 2024

Issued: 06 September 2024, London UK

 

GSK announces positive results from phase III trial of Nucala (mepolizumab) in
COPD

 

·   Primary endpoint met with a statistically significant and clinically
meaningful reduction in annualised rate of moderate/severe exacerbations vs.
placebo with data up to two years

 

GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE,
the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal
antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive
pulmonary disease (COPD).

 

The trial recruited COPD patients with broad clinical presentations of chronic
bronchitis and/or emphysema, who were receiving optimised inhaled maintenance
therapy. Participants were also required to have evidence of type 2
inflammation characterised by raised blood eosinophil count.(1) MATINEE met
its primary endpoint with the addition of Nucala to inhaled maintenance
therapy, and study results showed a statistically significant and clinically
meaningful reduction in the annualised rate of moderate/severe exacerbations
versus placebo with patients treated for up to 104 weeks.

( )

The preliminary safety results are consistent with the known safety profile of
Nucala. Further analysis of these data is ongoing.

 

COPD affects more than 300 million people globally with up to 40% of patients
exhibiting type 2 inflammation characterised by raised blood eosinophil count,
that drives exacerbations.(3,4) IL-5 is a key messenger protein (cytokine) in
type 2 inflammation.(5) Recurrent exacerbations lead to damage to the lungs,
progressive lung function decline and risk of hospitalisation. This can result
in a vicious cycle of deterioration in overall physical health, which leads to
worsening of symptoms and quality of life, and increased mortality.(6,7)

 

The full results of MATINEE will be presented at a future scientific congress
and will inform ongoing discussions with regulatory authorities. Nucala is
currently not indicated for COPD anywhere in the world.

 

About the mepolizumab development programme for COPD

The mepolizumab program in COPD is comprised of three clinical trials. The
first two studies, METREX and METREO, completed in 2017. MATINEE was designed
to supplement METREX and METREO, building on our learnings from these studies
and IL-5 science to identify the patients who could benefit the most from
Nucala and support future submissions and approvals for use in this
indication.(3)

 

MATINEE is a multi-centre, randomised, placebo controlled, double-blind,
parallel group study. The trial is designed to confirm the benefits of
mepolizumab treatment on moderate or severe exacerbations in 806 COPD
participants who were randomised to receive mepolizumab, or a placebo, as an
add on to their optimised maintenance COPD therapy for at least 52 weeks and
up to a maximum of 104 weeks.(1)

 

About Nucala

First approved in 2015 for severe asthma with an eosinophilic phenotype in the
US, mepolizumab is a monoclonal antibody that targets and binds to
interleukin-5 (IL-5), a key messenger protein (cytokine) in type 2
inflammation. Nucala has been developed for the treatment of a range of IL-5
mediated diseases associated with type 2 inflammation.

 

For product and important safety information please consult the country
relevant summary of product characteristics.

EU and UK available
at: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf
(https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf)

 

 

About chronic obstructive pulmonary disease (COPD)

COPD is the third leading cause of death worldwide with exacerbations
accounting for the greatest proportion of the total COPD burden on the
healthcare system.(2,) Patients with COPD have chronic inflammation leading to
persistent respiratory symptoms such as breathlessness and a productive cough.
The daily impact on patients' lives can lead to anxiety and depression.(6)
Exacerbations are acute episodes of worsening COPD symptoms and can result in
hospitalisation, irreversible and cumulative lung damage or death.(6) Many
patients continue to experience exacerbations despite standard treatment
meaning that there is a need for targeted therapies that address the
underlying pathobiology.(6,10,11) Up to 40% of patients have evidence of type
2 inflammation that drives exacerbations.(3,4) Blood eosinophil count is a
biomarker for type 2 inflammation that can be easily measured by a simple
blood test and indicates a patient's risk of exacerbation and deterioration,
and response to treatment in COPD.(6) ( )IL-5 is a core cytokine in type 2
inflammation. It is a major protein responsible for the growth, maturation,
activation and survival of eosinophils, a type of white blood cell implicated
in the pathogenesis of type 2 inflammatory diseases. Evidence indicates that
IL-5 has an impact on other cell types beyond eosinophils, including those
that contribute to inflammation, lung remodelling and disease
progression.(12-16)

 

About GSK in respiratory

GSK continues to build on decades of pioneering work to deliver more ambitious
treatment goals, develop the next generation standard of care, and redefine
the future of respiratory medicine for hundreds of millions of people with
respiratory diseases. With an industry-leading respiratory portfolio and
pipeline of vaccines, targeted biologics and inhaled medicines, we are focused
on improving outcomes and the lives of people living with all types of asthma
and COPD along with less understood refractory chronic cough or rarer
conditions like systemic sclerosis with interstitial lung disease. GSK is
harnessing the latest science and technology with the aim to modify underlying
disease dysfunction and prevent disease progression.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Sarah Clements     +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q2 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

References

1.    ClinicalTrials.gov.  Mepolizumab as Add-on Treatment IN Participants
With COPD Characterized by Frequent Exacerbations and Eosinophil Level
(MATINEE) Available at: https://clinicaltrials.gov/study/NCT04133909 Last
accessed July 2024
(https://clinicaltrials.gov/study/NCT04133909%20Last%20accessed%20July%202024)
.

2.    GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of
chronic respiratory diseases and risk factors, 1990-2019: an update from the
Global Burden of Disease Study 2019. Lancet. 2023:59;101936.

3.    Singh D, et al. ECLIPSE Investigators. Eosinophilic inflammation
in COPD: prevalence and clinical characteristics. Eur Respir
J. 2014;44:1697-1700.

4.    Saha S, et al. Eosinophilic airway inflammation in COPD. Int J Chron
Obstruct Pulmon Dis. 2006;1(1):39-47.

5.    Maspero J, et al. Type 2 inflammation in asthma and other airway
diseases. ERJ Open Res. 2022;8:00576-2021.

6.    GOLD Science Committee Members (2023-2024). The Global Strategy for
Diagnosis, Management and Prevention of CO 2024. Available at:
www.goldcopd.org (http://www.goldcopd.org) Last accessed: July 2024

7.    Hurst JR, et al. Susceptibility to Exacerbation in Chronic
Obstructive Pulmonary Disease. N Engl J Med. 2010;363:1128-1138.

8.    U.S. Food and Drug Administration. Nucala Full Prescribing
Information. Available at:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761122s000lbl.pdf
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761122s000lbl.pdf) .
Last accessed December 2023.

9.    European summary of product characteristics available at
https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf
last accessed February 2023
(https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf%20last%20accessed%20February%202023)

10.  Whittaker H, et al. Frequency and Severity of Exacerbations of COPD
Associated with Future Risk of Exacerbations and Mortality: A UK Routine
Health Care Data Study. Int J Chron Obstruct Pulmon Dis. 2022;17:427-437.

11.  Rabe KF, et al. Targeting Type 2 Inflammation and Epithelial Alarmins in
Chronic Obstructive Pulmonary Disease: A Biologics Outlook. Am J Respir Crit
Care Med. 2023;208:396-405.

12.  Buchheit KM, et al. Mepolizumab targets multiple immune cells in
aspirin-exacerbated respiratory disease. J Allergy Clin Immunol.
2021;148(2):574-584.

13.  Barretto KT, et al. Human airway epithelial cells express a functional
IL-5 receptor. Allergy. 2020;75(8):2127-2130.

14.  Bajbouj K, et al. IL-5 receptor expression in lung fibroblasts:
Potential role in airway remodelling in asthma. Allergy. 2023;78(3):882-885.

15.  Siddiqui S, et al. Eosinophils and tissue remodeling: Relevance to
airway disease. J Allergy Clin Immunol. 2023;152(4):841-857.

16.  Bergantini L, et al. Regulatory T cell monitoring in severe eosinophilic
asthma patients treated with mepolizumab. Scand J Immunol. 2021;94(1):e13031.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKPBDDBKBACK